Lyndse Ashley
Family · Norman, OKNPI 1861736738
Payments from drug & device makers
Across 440 payments — averaging $12.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- AbbVie$656
- Johnson & Johnson$467
- Otsuka America Pharmaceutical, Inc.$437
- Alkermes, Inc.$368
- Corium, LLC$341
- plus $2K from 21 others
What the payments were for
- Food & beverage$5,28199%
- Education$491%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$5,330 in reported general payments places this provider in the 90th percentile of 2,026 family providers in Oklahoma.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FetzimaLevomilnacipran Hcl | 12 | $6,405 |
| Bupropion XlBupropion Hcl | 75 | $1,851 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 18 | $1,463 |
| Oxcarbazepine | 25 | $1,278 |
| Fluoxetine Hcl | 90 | $718 |
| Aripiprazole | 30 | $701 |
| Ziprasidone Hcl | 14 | $615 |
| Hydroxyzine Hcl | 19 | $507 |
| Duloxetine Hcl | 37 | $497 |
| Buspirone Hcl | 44 | $414 |
| Trazodone Hcl | 54 | $370 |
| Zolpidem Tartrate | 30 | $365 |
| Quetiapine Fumarate | 26 | $316 |
| Topiramate | 16 | $299 |
| Clonidine Hcl | 36 | $227 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieFetzima | $656 | $6,40512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,026 family providers in Oklahoma.
Other family in Norman
- Brandy ReevesNorman$17K
- Katherine BuckNorman$14K
- Jackson LaizureNorman$13K
- Jordan HarrisNorman$12K
- Julie RobersonNorman$10K
- April WilcoxOklahoma City$245K
- Jeremy MorganOklahoma City$63K
- Samantha BellingerOklahoma City$39K
- Candy WilliamsTulsa$22K
- Lacey HillOklahoma City$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.